NASDAQ:POAI - Predictive Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 177.78 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.08
▼ -0.01 (-0.92%)
1 month | 3 months | 12 months
Get New Predictive Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for POAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for POAI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$3.00
▲ +177.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Predictive Oncology in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 177.78% upside from the last price of $1.08.
Buy
The current consensus among 1 investment analysts is to buy stock in Predictive Oncology.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2021Litchfield Hills ResearchInitiated CoverageBuy$3.00Low
i
(Data available from 4/22/2016 forward)
Predictive Oncology logo
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Read More

Today's Range

Now: $1.08
$1.05
$1.15

50 Day Range

MA: $1.36
$0.95
$1.76

52 Week Range

Now: $1.08
$0.63
$2.30

Volume

10,358 shs

Average Volume

4,639,380 shs

Market Capitalization

$52.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Predictive Oncology?

The following sell-side analysts have issued stock ratings on Predictive Oncology in the last year: Litchfield Hills Research.
View the latest analyst ratings for POAI.

What is the current price target for Predictive Oncology?

1 Wall Street analysts have set twelve-month price targets for Predictive Oncology in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 177.8%. Litchfield Hills Research has the highest price target set, predicting POAI will reach $3.00 in the next twelve months. Litchfield Hills Research has the lowest price target set, forecasting a price of $3.00 for Predictive Oncology in the next year.
View the latest price targets for POAI.

What is the current consensus analyst rating for Predictive Oncology?

Predictive Oncology currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe POAI will outperform the market and that investors should add to their positions of Predictive Oncology.
View the latest ratings for POAI.

What other companies compete with Predictive Oncology?

How do I contact Predictive Oncology's investor relations team?

Predictive Oncology's physical mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The medical instruments supplier's listed phone number is 651-389-4800 and its investor relations email address is [email protected] The official website for Predictive Oncology is www.precisiontherapeutics.com.